These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7686263)

  • 1. Antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA: applications for detection of xenobiotics in biological samples.
    Poirier MC
    Mutat Res; 1993 Jul; 288(1):31-8. PubMed ID: 7686263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoaffinity chromatography of carcinogen DNA adducts with polyclonal antibodies directed against benzo[a]pyrene diol-epoxide-DNA.
    Tierney B; Benson A; Garner RC
    J Natl Cancer Inst; 1986 Jul; 77(1):261-7. PubMed ID: 3459918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human exposure monitoring, dosimetry, and cancer risk assessment: the use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA.
    Poirier MC
    Drug Metab Rev; 1994; 26(1-2):87-109. PubMed ID: 8082583
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal antibodies and rabbit antisera recognizing 4-aminobiphenyl--DNA adducts and application to immunoaffinity chromatography.
    Groopman JD; Skipper PL; Donahue PR; Trudel LJ; Wildschutte M; Kadlubar FF; Tannenbaum SR
    Carcinogenesis; 1992 Jun; 13(6):917-22. PubMed ID: 1600611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring human exposure to carcinogens by DNA adduct measurement.
    Santella RM
    Cell Biol Toxicol; 1988 Dec; 4(4):511-6. PubMed ID: 3228719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of carcinogen-DNA adduct antisera for quantitation and localization of genomic damage in animal models and the human population.
    Poirier MC
    Environ Mutagen; 1984; 6(6):879-87. PubMed ID: 6389112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic methods for the detection of carcinogen adducts in humans.
    Santella RM; Yang XY; Hsieh LL; Young TL
    Prog Clin Biol Res; 1990; 340C():247-57. PubMed ID: 2199982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA adduct determination in humans.
    Poirier MC; Weston A
    Prog Clin Biol Res; 1991; 372():205-18. PubMed ID: 1956919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined micropreparative techniques with synchronous fluorescence spectroscopy or 32P-postlabelling assay for carcinogen-DNA adduct determination.
    Shields PG; Kato S; Bowman ED; Petruzzelli S; Cooper DP; Povey AC; Weston A
    IARC Sci Publ; 1993; (124):243-54. PubMed ID: 8225491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of immunoassays and fluorometry to the detection of polycyclic hydrocarbon-macromolecular adducts and anti-adduct antibodies in humans.
    Weston A; Rowe M; Poirier M; Trivers G; Vahakangas K; Newman M; Haugen A; Manchester D; Mann D; Harris C
    Int Arch Occup Environ Health; 1988; 60(3):157-62. PubMed ID: 3384480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical methods for the detection of carcinogen-DNA adducts in humans.
    Weston A
    Mutat Res; 1993 Jul; 288(1):19-29. PubMed ID: 7686262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 32P-postlabelling and mass spectrometric methods for analysis of bulky, polyaromatic carcinogen-DNA adducts in humans.
    Talaska G; Roh JH; Getek T
    J Chromatogr; 1992 Sep; 580(1-2):293-323. PubMed ID: 1400827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological detection and quantification of carcinogen-modified DNA components.
    Müller R; Adamkiewicz J; Rajewsky MF
    IARC Sci Publ; 1982; (39):463-79. PubMed ID: 6759386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of carcinogen-DNA adducts by immunoassay.
    Poirier MC; Liou SH; Reed E; Strickland PT; Tockman MS
    J UOEH; 1989 Mar; 11 Suppl():353-67. PubMed ID: 2664949
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA repair in human cells: quantitative assessment of bulky anti-BPDE-DNA adducts by non-competitive immunoassays.
    Venkatachalam S; Denissenko M; Wani AA
    Carcinogenesis; 1995 Sep; 16(9):2029-36. PubMed ID: 7554050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological methods for detection of carcinogen-DNA damage in humans.
    Santella RM
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):733-9. PubMed ID: 10498391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interlaboratory comparison of antisera and immunoassays for benzo[a]pyrene-diol-epoxide-I-modified DNA.
    Santella RM; Weston A; Perera FP; Trivers GT; Harris CC; Young TL; Nguyen D; Lee BM; Poirier MC
    Carcinogenesis; 1988 Jul; 9(7):1265-9. PubMed ID: 3133129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of carcinogen-DNA adducts by a standardized high-sensitive enzyme immunoassay.
    Kriek E; Welling M; van der Laken CJ
    IARC Sci Publ; 1984; (59):297-305. PubMed ID: 6400097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding efficiency of polyclonal and monoclonal antibodies to DNA modified with benzo[a]pyrene diol epoxide is dependent on the level of modification. Implications for quantitation of benzo[a]pyrene-DNA adducts in vivo.
    Van Schooten FJ; Kriek E; Steenwinkel MJ; Noteborn HP; Hillebrand MJ; Van Leeuwen FE
    Carcinogenesis; 1987 Sep; 8(9):1263-9. PubMed ID: 3113753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of human exposure to carcinogens by measurement of alkyl-DNA adducts using immunoaffinity clean-up in combination with gas chromatography-mass spectrometry and other methods of quantitation.
    Shuker DE; Bartsch H
    Mutat Res; 1994; 313(2-3):263-8. PubMed ID: 7523910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.